Table 2 Log MAR visual acuity and vision‐related quality of life before enrolment in study and 3 months after systemic immunosuppression.
| Baseline n (%) | 3 months n (%) | |
|---|---|---|
| VA—worse eye | ||
| 0–0.28 | 12 (32) | 20 (54) |
| 0.3–0.58 | 7 (19) | 5 (14) |
| 0.6–0.78 | 5 (14) | 1 (3) |
| 0.8–1 | 2 (5) | 5 (14) |
| >1 | 11 (30) | 6 (16) |
| VA—better eye | ||
| 0–0.28 | 25 (68) | 29 (78) |
| 0.3–0.58 | 7 (19) | 6 (16) |
| 0.6–0.78 | 2 (5) | 1 (3) |
| 0.8–1 | 3 (8) | 1 (3) |
| >1 | 0 (0) | 0 (0) |
| VCM1 score | ||
| 0–1 | 9 (24) | 20 (54) |
| 1.1–2 | 13 (35) | 7 (19) |
| 2.1–3 | 11 (30) | 9 (24) |
| 3.1–4 | 4 (11) | 1 (3) |
| 4.1–5 | 0 (0) | 0 (0) |
VA, visual acuity; VCM1, vision core module 1.